Dr. Narayan on efficacy, tolerability of nadofaragene firadenovec in BCG-unresponsive NMIBC

Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.

Vikram M. Narayan, MD, highlights efficacy and safety data with the novel intravesical gene-mediated therapy nadofaragene firadenovec in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.

In a phase 3 trial nadofaragene firadenovec achieved a complete response (CR) rate of 53.4% at 3 months in a subgroup of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 disease. The 12-month CR rate was 24.3% and the median duration of CR was 9.69 months in these patients.

Related Videos
Sophia Kamran, MD, answers a question during a Zoom video interview
Eric A. Singer, MD, MA, FACS, an expert on bladder cancer
Eric A. Singer, MD, MA, FACS, an expert on bladder cancer
Eric A. Singer, MD, MA, FACS, an expert on bladder cancer
Eric A. Singer, MD, MA, FACS, an expert on bladder cancer
Dr. Diana Magee in an interview with Urology Times
Dr. Brian Chun in an interview with Urology Times
Related Content
© 2023 MJH Life Sciences

All rights reserved.